{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:34:42Z","timestamp":1786739682293,"version":"build-2736575974"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Retinal dysfunction is the most common cause of vision loss in several retinal disorders. It has been estimated a great increase in these pathologies that are becoming more globally widespread and numerous over time, also supported by the life expectancy increment. Among different types of retinopathies, we can account some that share causes, symptoms, and treatment including diabetic retinopathy, age-related macular degeneration, glaucoma, and retinitis pigmentosa. Molecular changes, environmental factors, and genetic predisposition might be some of the main causes that drive retinal tissue to chronic inflammation and neurodegeneration in these retinopathies. The treatments available on the market contain compounds that efficiently ameliorate some of the important clinical features of these pathologies like stabilization of the intraocular pressure, reduction of eye inflammation, control of eye oxidative stress which are considered the major molecular mechanisms related to retinal dysfunction. Indeed, the most commonly used drugs are anti-inflammatories, such as corticosteroids, antioxidant, hypotonic molecules and natural neuroprotective compounds. Unfortunately, these drugs, which are fundamental to treating disease symptoms, are not capable to cure the pathologies and so they are not life-changing for patients. This review provided an overview of current treatments on the market, but more interestingly, wants to be a quick window on the new treatments that are now in clinical trials. Additionally, it has been here highlighted that the recent technical enhancement of the investigation methods to identify the various retinopathies causes might be used as a sort of \u201cprecise medicine\u201d approach to tailor the identification of molecular pathways involved and potentially study a dedicated treatment for each patient. This approach includes the use of cutting-edge technologies like gene therapy and metabolomics.<\/jats:p>","DOI":"10.4103\/1673-5374.373662","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:05:14Z","timestamp":1684411514000},"page":"2619-2622","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Retinoprotective compounds, current efficacy, and future prospective"],"prefix":"10.4103","volume":"18","author":[{"given":"Rachele","family":"Marino","sequence":"first","affiliation":[{"name":"Laboratory of Neuronal Cell Signaling, EBRI Rita Levi-Montalcini Foundation, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Sappington","sequence":"additional","affiliation":[{"name":"Department of Neurobiology and Anatomy, Wake Forest School of Medicine, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC, USA"},{"name":"Department of Ophthalmology, Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7070-9662","authenticated-orcid":false,"given":"Marco","family":"Feligioni","sequence":"additional","affiliation":[{"name":"Laboratory of Neuronal Cell Signaling, EBRI Rita Levi-Montalcini Foundation, Rome, Italy"},{"name":"Department of Neurorehabilitation Sciences, Casa di Cura Igea, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"key":"R1-20260525","first-page":"10","article-title":"Lutein as a modulator of oxidative stress-mediated inflammatory diseases","volume":"13","author":"Ahn","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"R2-20260525","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3390\/ijms21072262","article-title":"Neuroprotective strategies for retinal ganglion cell degeneration:Current status and challenges ahead","volume":"21","author":"Boia","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R3-20260525","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1167\/tvst.11.10.37","article-title":"Danicopan, an oral complement factor D inhibitor, exhibits high and sustained exposure in ocular tissues in preclinical studies","volume":"11","author":"Boyer","year":"2022","journal-title":"Transl Vis Sci Technol"},{"key":"R4-20260525","first-page":"1141","article-title":"New thiophene\u2013acridine compounds:synthesis, antileishmanial activity, DNA binding, chemometric, and molecular docking studies","volume":"91","author":"de","year":"2018","journal-title":"ChemBiol Drug Des"},{"key":"R5-20260525","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ophtha.2018.09.041","article-title":"Macular Telangiectasia Type 2-Phase 2 CNTF Research Group (2019) Effect of ciliary neurotrophic factor on retinal neurodegeneration in patients with macular telangiectasia type 2:a randomized clinical trial","volume":"126","author":"Chew","journal-title":"Ophthalmology"},{"key":"R6-20260525","first-page":"27","article-title":"Oral drug pipeline for retinal disease","volume":"19","author":"DeBoer","year":"2022","journal-title":"Retinal Physician"},{"key":"R7-20260525","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.4103\/1673-5374.274325","article-title":"Beneficial effects of saffron (Crocus sativus L.). in ocular pathologies, particularly neurodegenerative retinal diseases","volume":"15","author":"Fern\u00e1ndez-Albarral","year":"2020","journal-title":"Neural Regen Res"},{"key":"R8-20260525","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11033-020-06032-y","article-title":"Pemafibrate prevents retinal neuronal cell death in NMDA-induced excitotoxicity via inhibition of p-c-Jun expression","volume":"48","author":"Fujita","year":"2021","journal-title":"Mol Biol Rep"},{"key":"R9-20260525","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/ceo.13702","article-title":"Local delivery of corticosteroids in clinical ophthalmology:a review","volume":"48","author":"Fung","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"key":"R10-20260525","doi-asserted-by":"crossref","first-page":"8923615","DOI":"10.1155\/2022\/8923615","article-title":"Protective effect of curcuma extract in an ex vivo model of retinal degeneration via antioxidant activity and targeting the SUMOylation","author":"Hassanzadeh","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"R11-20260525","first-page":"133","article-title":"APE1\/Ref-1 as a novel target for retinal diseases","volume":"2","author":"Heisel","year":"2021","journal-title":"J Cell Signal"},{"key":"R12-20260525","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/14656566.2018.1448060","article-title":"Pharmacotherapy of retinal disease with visual cycle modulators","volume":"19","author":"Hussain","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"R13-20260525","doi-asserted-by":"crossref","first-page":"174032","DOI":"10.1016\/j.ejphar.2021.174032","article-title":"Effect of dual PPAR-\u03b1\/\u03b3agonist saroglitazar on diabetic retinopathy and oxygen-induced retinopathy","volume":"899","author":"Joharapurkar","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"R14-20260525","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3390\/ijms23010386","article-title":"The role of inflammation in retinal neurodegeneration and degenerative diseases","volume":"23","author":"Kaur","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R15-20260525","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000259897","article-title":"Anti-glycation and anti-albuminuric effects of GLY-230 in human diabetes","volume":"31","author":"Kennedy","year":"2010","journal-title":"Am J Nephrol"},{"key":"R16-20260525","doi-asserted-by":"crossref","first-page":"113856","DOI":"10.1016\/j.ejmech.2021.113856","article-title":"Retinol binding protein 4 antagonists and protein synthesis inhibitors:potential for therapeutic development","volume":"226","author":"Kim","year":"2021","journal-title":"Eur J Med Chem"},{"key":"R17-20260525","first-page":"4281","article-title":"OCX063, a novel small molecule drug, is protective against inflammatory, fibrotic and angiogenic phenotypes in retinal cultures","volume":"61","author":"Kong","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R18-20260525","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/bjophthalmol-2020-317712","article-title":"Randomised study evaluating the pharmacodynamics of emixustat hydrochloride in subjects with macular atrophy secondary to Stargardt disease","volume":"106","author":"Kubota","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R19-20260525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antiox10030386","article-title":"Antioxidant activity and neuroprotective role of docosahexaenoic acid (Dha) supplementation in eye diseases that can lead to blindness:a narrative review","volume":"10","author":"Lafuente","year":"2021","journal-title":"Antioxidants"},{"key":"R20-20260525","doi-asserted-by":"crossref","first-page":"875662","DOI":"10.3389\/fphar.2022.875662","article-title":"Brain-derived neurotrophic factor-mediated neuroprotection in glaucoma:a review of current state of the art","volume":"13","author":"Lambuk","year":"2022","journal-title":"Front Pharmacol"},{"key":"R21-20260525","first-page":"944","article-title":"Metabolomics in retinal diseases:an update","volume":"10","author":"Li","year":"2021","journal-title":"Biology (Basel)"},{"key":"R22-20260525","first-page":"1","article-title":"Neurotrophic factors in glaucoma and innovative delivery systems","volume":"10","author":"Mallone","year":"2020","journal-title":"Applied Sciences (Switzerland)"},{"key":"R23-20260525","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.3390\/cells10092394","article-title":"Ocular neurodegenerative diseases:Interconnection between retina and cortical areas","volume":"10","author":"Marchesi","year":"2021","journal-title":"Cells"},{"key":"R24-20260525","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1055\/a-0947-5712","article-title":"Neuroprotective potential of ginkgo biloba in retinal diseases","volume":"85","author":"Mart\u00ednez-Sol\u00eds","year":"2019","journal-title":"Planta Med"},{"key":"R25-20260525","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.3390\/nu14142963","article-title":"Citicoline\/coenzyme Q10\/vitamin B3 fixed combination exerts synergistic protective effects on neuronal cells exposed to oxidative stress","volume":"14","author":"Mastropasqua","year":"2022","journal-title":"Nutrients"},{"key":"R26-20260525","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s13311-019-00786-5","article-title":"Connexin hemichannel block using orally delivered tonabersat improves outcomes in animal models of retinal disease","volume":"17","author":"Mat","year":"2020","journal-title":"Neurotherapeutics"},{"key":"R27-20260525","doi-asserted-by":"crossref","first-page":"601647","DOI":"10.3389\/fphar.2020.601647","article-title":"Biomarkers of neurodegeneration and precision therapy in retinal disease","volume":"11","author":"Micera","year":"2021","journal-title":"Front Pharmacol"},{"key":"R28-20260525","doi-asserted-by":"crossref","first-page":"159070","DOI":"10.1016\/j.bbalip.2021.159070","article-title":"Fenretinide inhibits vitamin A formation from \u03b2-carotene and regulates carotenoid levels in mice","author":"Miller","year":"2022","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"R29-20260525","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1097\/IAE.0000000000003571","article-title":"Human cellular models for retinal disease:from induced pluripotent stem cells to organoids","volume":"42","author":"Mustafi","year":"2022","journal-title":"Retina"},{"key":"R30-20260525","doi-asserted-by":"crossref","DOI":"10.36118\/pharmadvances.2022.28","article-title":"Pricing for multi indication medicines:a discussion with italian experts","author":"Pani","year":"2022","journal-title":"Pharmadvances"},{"key":"R31-20260525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antiox9080761","article-title":"Oxidative stress and vascular dysfunction in the retina:therapeutic strategies","volume":"9","author":"Ruan","year":"2020","journal-title":"Antioxidants"},{"key":"R32-20260525","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/APO.0000000000000291","article-title":"Emerging therapies in neovascular age-related macular degeneration in 2020","volume":"9","author":"Samanta","year":"2020","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"R33-20260525","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archopht.126.6.793","article-title":"Rosiglitazone and delayed onset of proliferative diabetic retinopathy","volume":"126","author":"Shen","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"R34-20260525","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archopht.126.6.793","article-title":"Rosiglitazone and delayed onset of proliferative diabetic retinopathy","volume":"126","author":"Shen","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"R35-20260525","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3390\/genes13071233","article-title":"Molecular genetic mechanisms in age-related macular degeneration","volume":"13","author":"Shughoury","year":"2022","journal-title":"Genes (Basel)"},{"key":"R37-20260525","doi-asserted-by":"crossref","first-page":"e0239108","DOI":"10.1371\/journal.pone.0239108","article-title":"Minocycline decreases CCR2-positive monocytes in the retina and ameliorates photoreceptor degeneration in a mouse model of retinitis pigmentosa","volume":"16","author":"Terauchi","year":"2021","journal-title":"PLoS One"},{"key":"R38-20260525","doi-asserted-by":"crossref","first-page":"903436","DOI":"10.3389\/fcell.2022.903436","article-title":"Valproic acid reduces neuroinflammation to provide retinal ganglion cell neuroprotection in the retina axotomy model","volume":"10","author":"Tribble","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"R39-20260525","doi-asserted-by":"crossref","first-page":"7836828","DOI":"10.1155\/2022\/7836828","article-title":"Role of oxidative stress in retinal disease and the early intervention strategies:a review","author":"Wang","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"R40-20260525","doi-asserted-by":"crossref","first-page":"749858","DOI":"10.3389\/fphar.2021.749858","article-title":"Topical medication therapy for glaucoma and ocular hypertension","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"R41-20260525","first-page":"724648","article-title":"Inflammation in retinal disease","author":"Whitcup","year":"2013","journal-title":"Int J Inflam"},{"key":"R42-20260525","doi-asserted-by":"crossref","first-page":"894","DOI":"10.18240\/ijo.2022.06.06","article-title":"miRNA-451 regulates rhesus choroid-retinal endothelial cell function and proteome profile","volume":"15","author":"Wu","year":"2022","journal-title":"Int J Ophthalmol"},{"key":"R43-20260525","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.2147\/DDDT.S383101","article-title":"Progress and challenges of anti-VEGF agents and their sustained-release strategies for retinal angiogenesis","volume":"16","author":"Xu","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"R44-20260525","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/mds.27353","article-title":"Randomized, clinical trial of RT001:Early signals of efficacy in Friedreich's ataxia","volume":"33","author":"Zesiewicz","year":"2018","journal-title":"Mov Disord"},{"key":"R45-20260525","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.3390\/cells10061426","article-title":"Retinal ganglion cell transplantation:approaches for overcoming challenges to functional integration","volume":"10","author":"Zhang","year":"2021","journal-title":"Cells"}],"container-title":["Neural Regeneration Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/1673-5374.373662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:31:17Z","timestamp":1786735877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1673-5374.373662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/1673-5374.373662","relation":{},"ISSN":["1673-5374","1876-7958"],"issn-type":[{"value":"1673-5374","type":"print"},{"value":"1876-7958","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,10]]},"assertion":[{"value":"2022-11-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}